InMed Pharmaceuticals Inc. (INM) CEO Eric Adams on Q3 2021 Results - Earnings Call Transcript

InMed Pharmaceuticals Inc. (NASDAQ:INM) Q3 2021 Earnings Conference Call May 13, 2021 11:00 AM ET

Company Participants

Bruce Colwill - Chief Financial Officer
Eric Adams - President and Chief Executive Officer
Eric Hsu - Senior Vice President, Preclinical Research and Development
Alexandra Mancini - Senior Vice President, Clinical and Regulatory Affairs
Michael Woudenberg - Vice President, Chemistry, Manufacturing and Control

Conference Call Participants

Scott Henry - ROTH Capital Markets

Operator

Good morning. My name is Sara and I will be your conference operator today. At this time, I would like to welcome everyone to InMed’s Third Quarter 2021 Financial Results and Business Update Conference Call for the fiscal quarter ended March 31, 2021. [Operator Instructions] Mr. Colwill, you may begin your conference.

Bruce Colwill

Thank you, Sarah. Good day, everyone. My name is Bruce Colwill and I am InMed’s Chief Financial Officer and welcome to InMed’s Third Quarter of 2021 Financial Results and Business Update Conference Call. Please note that we are once again all joining today from remote locations, so we appreciate your patience as we happen to encounter any unexpected technical challenges today.

But before we begin, we would like to go over our disclosure statements, followed by a review of the progress of our therapeutic development in cannabinoid manufacturing programs, which will be led by our President and CEO, Eric Adams. After which, I will review the financial results of operations. Following that, we will be available for a question-and-answer session. Also joining us today to address your questions Eric Hsu, Senior Vice President of Preclinical Research and Development; Alexandra Mancini, Senior Vice President, Clinical and Regulatory Affairs; and Michael Woudenberg, Vice President of Chemistry, Manufacturing and Control.

Please be advised that certain statements in the following conference call regarding expectations for InMed’s business operations, clinical development, key personnel, contractual